Navigation Links
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Date:6/1/2009

Cimzia(R) shows duration of response up to week 26 in moderate to severe Crohn's patients who failed the intravenous infusion treatment infliximab.

CHICAGO, June 1 /PRNewswire/ -- New data from the WELCOME study presented by UCB at the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab pegol) provides sustained symptom improvement with stable dosing through week 26 for adult patients suffering from moderate to severe Crohn's disease (CD) who are intolerant or no longer responding to Remicade(R) (infliximab). Cimzia(R) is approved for reducing signs and symptoms of moderate to severe Crohn's disease and maintaining clinical response in adult patients who have had an inadequate response to conventional therapy. Cimzia is the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha).

"These are important findings as Cimzia(R) shows an extended duration of response in an induction and maintenance clinical trial of Crohn's disease patients who have failed infliximab," said study investigator Douglas Wolf, M.D., Atlanta Gastroenterology Associates, Atlanta, GA. "The study demonstrates that Cimzia(R) is effective up to 26 weeks in this difficult to treat patient population."

The primary objective of WELCOME is to assess the clinical efficacy of Cimzia(R) (400 mg) at week 6 following an induction, in moderate to severe Crohn's disease patients who have previously received and responded but who no longer have a sustained response and/or tolerance to infliximab. Primary efficacy was defined as at least 100 points decrease in the Crohn's Disease Activity Index (CDAI) versus baseline at week 6. The trial demonstrated that after the induction period 62 percent of patients achieved response and 39 percent achieved remission. 33 percent responded to treatment by week 2 and 44 percent responded by week 4. By week 26, nearly a third of patients receiving Cimzia(R) (400 mg) subcutaneously every two or fo
'/>"/>

SOURCE UCB, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. New Data Suggest CIMZIA(R) (Certolizumab Pegol) Active in Treating Moderate to Severe Crohns Patients With Fistulizing Disease
2. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
3. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
4. Reorganizational Healing Provides Access to Greater Quality of Life, Reduced Stress
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Resverlogix Provides Quarterly Update
7. China Sky One Medical, Inc. Provides Update on Filing Form 10-K
8. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
9. US Oncology Provides Full Service Management of Clinical Trials
10. SemBioSys provides update on insulin program
11. Cochlear Americas Provides Support for Cochlear Implant Recipients to Pursue Higher Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)...  Kainos Capital, a firm specializing in acquiring and ... has acquired the Slim-Fast brand from Unilever. Unilever will ... the transaction were not disclosed. Slim-Fast is ... markets ready-to-drink shakes, powders, bars and snacks to retail ... in the United Kingdom and ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... SAN FRANCISCO, March 20, 2012 /PRNewswire/ -- ... focused on the development and commercialization of first-in-class ... that the first patient has been treated in ... patients with metastatic colorectal cancer who have become ...
... GARDEN CITY, England and BOSTON, Massachusetts, March 20, 2012 ... discovery company, announces that an operating company of Shire ... global specialty biopharmaceutical company, has exercised its exclusive option ... discovered by Heptares that is currently in preclinical development. ...
... Holdings, Inc. (OTCQB: ONVO) ("Organovo") today announced the ... At the final closing, the Company raised gross proceeds ... Units, at a price of $1.00 per Unit, to ... of common stock issued and outstanding. As ...
Cached Biology Technology:Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 2Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 3Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 4Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer 5Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 2Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications 3
(Date:7/10/2014)... 3, 2014 According to the ... (Swipe And Area), Material (Optical Prism, Pizeoelectric, Capacitive, and ... and Banking & Finance), and Geography - Global Trends ... the global Fingerprint Sensors Market is projected to cross ... of 16.8% from 2014 to 2020. Browse ...
(Date:7/10/2014)... York , July 7, 2014 ... Transparency Market Research "Electronic Access Control Systems Market Global ... - 2019," the global Electronic Access Control systems market ... is expected to grow at a CAGR of 12.6% ... of USD 31,187.8 million in 2019. Browse ...
(Date:7/10/2014)... NORTHFIELD, Ill. , July 9, 2014 /PRNewswire-USNewswire/ ... record (EHR), spurred in large part by meaningful ... way health care providers interact with laboratory information. ... well-versed in the field of clinical informatics in ... care. To address the educational needs ...
Breaking Biology News(10 mins):Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5New Clinical Informatics Curriculum Prepares Future Pathologists 2New Clinical Informatics Curriculum Prepares Future Pathologists 3New Clinical Informatics Curriculum Prepares Future Pathologists 4
... (Santa Barbara, Calif.) A newly discovered species of monitor ... in the journal Zootaxa this week by a ... Sam Sweet, a professor in the department of Ecology, ... graduate student at Abo Akademi University in Turku, Finland, are ...
... live in the nicest possible house, ideally with regular ... School of Arts and Sciences and the New England ... improved housing using previously unknown social networking skills. ... models to uncover some surprising new tricks that could ...
... MD The Genetics Society of America is pleased ... for poster awards at the 51st Annual Drosophila Research ... selected for first, second and third place awards for ... This was the first time that undergraduate student research ...
Cached Biology News:New monitor lizard discovered in Indonesia 2Social networking helps hermit crabs find homes 2Social networking helps hermit crabs find homes 3Genetics Society of America announces award recipients at 51st Annual Drosophila Conference 2
Contact us for more information...
... System enables you to insert a transposable ... DNA by in vitro transposition. It uses ... into the DNA target. Target DNA may ... DNA, depending on your interests (6-8). If ...
... APAgene kits are designed to rapidly ... using our patented APA Technology. ... at an extraordinarily competitive price. All ... kit. The Locator Kit can be ...
... c-Jun N-terminal kinase (JNK) is one ... Firefly luciferase has been used as a ... function. Luciferase provides a 1000-fold increase in ... acetyltransferase (CAT) assay. Firefly luciferase catalyzes the ...
Biology Products: